CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 119 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45,510,022 | +89.9% | 1,530,263 | +15.0% | 1.54% | +161.5% |
| Q2 2023 | $23,971,339 | +12.2% | 1,330,263 | 0.0% | 0.59% | -14.7% |
| Q1 2023 | $21,364,024 | -12.2% | 1,330,263 | 0.0% | 0.69% | -7.2% |
| Q4 2022 | $24,343,813 | -6.8% | 1,330,263 | 0.0% | 0.74% | -3.9% |
| Q3 2022 | $26,126,000 | +5.3% | 1,330,263 | 0.0% | 0.77% | -9.9% |
| Q2 2022 | $24,809,000 | +43.0% | 1,330,263 | +68.3% | 0.86% | +57.6% |
| Q1 2022 | $17,345,000 | +3.4% | 790,209 | +33.9% | 0.54% | +1.7% |
| Q4 2021 | $16,767,000 | +11.3% | 590,169 | -31.4% | 0.53% | -52.0% |
| Q2 2020 | $15,064,000 | +192.8% | 859,802 | +145.7% | 1.11% | +107.1% |
| Q1 2020 | $5,145,000 | – | 350,000 | – | 0.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |